We are committed to provide our readers with leading information on all aspects of MS, NMO and related autoimmune diseases of the central nervous system.
Our journals are part of the international community of
@ECTRIMS@ACTRIMS@PACTRIMS_admin@lactrims_org and @eurims
You can read our articles on:
Multiple Sclerosis Journal https://t.co/Z2zC18ZbVk
MSJ Experimental Translational and Clinical https://t.co/XSjbuKwfiR
@MSJ_Research@inhabiz@SKKUni1398 Important paper-shaped signal: systemic immune dysregulation precedes demyelination by years, not weeks. Overall RR 1.58 in the decade before MS, wide tail: SLE 15.4, Sjögren's 10.5. Does prodromal autoimmunity mask or delay the MS diagnosis?
The burden of autoimmune disease is increased before formal diagnosis of #MultipleSclerosis and neuromyelitis optica spectrum disorder #NMOSD.
A nationwide Korean cohort study from @inhabiz@SKKUni1398 ▶️ https://t.co/Yviyc6J18P
...and letter from @UiB: Both rituximab and ocrelizumab were associated with very low disease activity, without established differences in relapse suppression.
🔽
https://t.co/vYt8xKOEUD
Rituximab may be inferior to ocrelizumab for relapse suppression (ARR 0.05 vs 0.03), though the rarity of relapses underpowered comparisons.
Study from @UAlberta@UBC ▶️ https://t.co/0E82eOOGwV
The absence of relative lymphocytosis is associated with anti-natalizumab antibody responses and may provide a simple biomarker to prompt anti-drug antibody testing before #MultipleSclerosis breakthrough occurs.
Study from @QMUL ▶️ https://t.co/tXLpoApAeF
Variability in access to key paraclinical tests may impact on the implementation of the 2024 McDonald criteria for the diagnosis of #MultipleSclerosis globally.
A global perspective from @DrWBRO@UCLIoN@QSMSCENTRE@MarTintore@cemcat_em ▶️ https://t.co/Skm4ukY3Ao
People with #MultipleSclerosis with progressive course, anxiety-related disorders and absence of self-reported cognitive concerns, are more likely to decline neurocognitive testing.
Study from @Sunnybrook@UofT ▶️ https://t.co/fmoVsYV4Yw
Researchers examined dropout in a long-term MS observational cohort: 26.9% at 5 yrs, 38.6% at 10 yrs. They report that dropouts had worse early disease characteristics and recommend including them in analyses to limit survivorship bias.
#MultipleSclerosis#analysis#bias
Ocrevus Vs. Tysabri. This cross sectional study looked at Octave MSDA scores (a biomarker which correlates with MS relapses and new MRI lesions) in people with MS, and those getting ocrevus were more likely to have low scores (98.1% vs. 66%). https://t.co/z7N1wiJ7pZ
In a long-term observational #MultipleSclerosis cohort, fewer than half completed the study, potentially causing underestimation of progression and reduced statistical power.
Study from @MScentrum020@amsterdamumc ▶️ https://t.co/3f9jnsLJIx
The cases below show that antibody-mediated neurological disorders may sometimes be a manifestation of inherited disorders of immune tolerance.
Commentary from @DrWBRO@uclh ▶️ https://t.co/YOqTBqp9Oq
1/🧵
Case report from @SunYatsen_Uni: Myelin oligodendrocyte glycoprotein antibody-associated disease #MOGAD in a patient with AIRE gene dominant-negative mutation.
🔽
https://t.co/RGHWKITQjR
2/🧵
🎓The ECTRIMS Fellowship Programme offers a valuable opportunity to enhance your expertise and advance your career in #MSResearch and care.
Apply by 1 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 2026: https://t.co/Otmd3MpgdG
#ECTRIMSFellowships#ECTRIMSNextGen#ApplyNow#MSResearch #HealthcareProfessionals #Neurology #AdvanceYourCareer
🔊 Listen to Claudia Zbrzeski and Stephen Krieger @IcahnMountSinai on how well junior neurology residents recognize #MultipleSclerosis.
📄 And read the full manuscript ▶️ https://t.co/rakpKCTWFg
💡𝐍𝐨𝐭 𝐞𝐯𝐞𝐫𝐲 𝐧𝐞𝐰 𝐬𝐲𝐦𝐩𝐭𝐨𝐦 𝐢𝐬 𝐧𝐞𝐜𝐞𝐬𝐬𝐚𝐫𝐢𝐥𝐲 𝐌𝐒 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧.
As we get older, distinguishing between the effects of MS, ageing and other health conditions can become increasingly challenging.
At Patient Community Day 2026, one speaker shared an important reminder: looking after your overall health matters just as much as managing your neurological condition.
And when it comes to exercise, small steps count. That’s the message from Stephanie Buxhoeveden, the Chief Scientific Officer at Accelerated Cure Project for Multiple Sclerosis, who also lives with MS.
Ten or fifteen minutes of movement throughout the day may be more manageable than one long workout. The key is finding something that works for you.
🎥 𝐖𝐚𝐭𝐜𝐡 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 4 𝐨𝐟 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐃𝐚𝐲 2026 𝐭𝐨 𝐡𝐞𝐚𝐫 𝐝𝐢𝐫𝐞𝐜𝐭𝐥𝐲 𝐟𝐫𝐨𝐦 𝐌𝐒 𝐞𝐱𝐩𝐞𝐫𝐭𝐬 𝐚𝐧𝐝 𝐩𝐞𝐨𝐩𝐥𝐞 𝐰𝐢𝐭𝐡 𝐥𝐢𝐯𝐞𝐝 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞: https://t.co/Jgr9oknsgv
@ECTRIMS #PatientCommunityDay #MSAwareness #HealthyAgeing #ECTRIMS
Mothers with #MultipleSclerosis, epilepsy, inflammatory bowel disease and diabetes share an elevated risk of mental illness in serial pregnancies, including depression, anxiety and bipolar disorder.
Study from @DalhousieU@UWaterloo ▶️ https://t.co/BdSTnHFpP4
Irreversible disability worsening was rare in neuromyelitis optica spectrum disease #NMOSD, and was independent of relapses in only 2% of patients.
Study from @MelbourneOf@TheRMH@MSBase_Registry ▶️ https://t.co/S6awJ3dhon
Autologous haematopoietic stem cell transplantation may accelerate resolution of paramagnetic rim lesions in #MultipleSclerosis, suggesting an effect within the central nervous system on microglia/macrophages.
Study from @UNI_FIRENZE@AOUCareggi ▶️ https://t.co/s4fxrTJHqo
There is an increasing number of people experiencing housing insecurity and forcible displacement globally, but more data are needed to understand the defined risks to persons with #MultipleSclerosis.
A scoping review from @HopkinsMedicine ▶️ https://t.co/lhCbKuvyVI